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Various α2,3 subtype selective partial GABA-A agonists are in development to treat anxiety disorders. These compounds are
expected to be anxiolytic with fewer undesirable side eﬀects, compared to nonselective GABA-A agonists like benzodiazepines.
Several α2,3 subtype selective and nonselective GABA-A agonists have been examined in healthy volunteers, using a battery
addressing diﬀerent brain domains. Data from ﬁve placebo-controlled double-blind studies were pooled. Lorazepam 2mg was
the comparator in three studies. Three α2,3-selective GABAA agonists (i.e., TPA023, TPACMP2, SL65.1498), one α1-selective
GABAA agonists (zolpidem), and another full agonist (alprazolam) were examined. Pharmacological selectivity was assessed by
determinationofregressionlinesforthechangefrombaselineofsaccadic-peak-velocity-(ΔSPV-)relativeeﬀect,relativetochanges
in diﬀerent pharmacodynamic endpoints (ΔPD). SPV was chosen for its sensitivity to the anxiolysis of benzodiazepines. Slopes
of the ΔSPV-ΔPD relations were consistently lower with the α2,3 selective GABA-A agonists than with lorazepam, indicating that
their PD eﬀects are less than their SPV-eﬀects. The ΔSPV-ΔPD relations of lorazepam were comparable to alprazolam. Zolpidem
showed relatively higher impairments in ΔPD relative to ΔSPV, but did not signiﬁcantly diﬀer from lorazepam. These PD results
support the pharmacological selectivity of the α2,3-selective GABA-A agonists, implying an improved therapeutic window.
1.Introduction
Anxiety is a psychological and physiological state with so-
matic, emotional, cognitive, and behavioral components [1],
which dominates thinking and leads to disturbance of daily
functioning. Serotonergic antidepressants, either selective
serotonin reuptake inhibitors (SSRIs) or serotonin-norepi-
nephrine reuptake inhibitors (SNRIs), are currently pre-
scribedasthe1st-linetreatmentforseveralanxietydisorders.
However, the slow onset of therapeutic eﬀect and the
presence of sexual side eﬀects prevent these drugs from more
extensive use and lead to lack of treatment compliance [2].
Moreover, SSRIs/SNRIs cause transient increase of anxiety
duringtheﬁrstfewweeksofadministration.Alltheseclinical
experiences provide space for the use of benzodiazepines
(BZDs) in acute anxiety episodes.
Benzodiazepines are the most commonly prescribed
anxiolytic drugs, although treatment guidelines generally
limit their use to several weeks to prevent the occurrence
of tolerance and dependence. Benzodiazepines are allosteric
modulators of the GABAA receptors that aﬀect the central
nervous system (CNS) as full GABAergic agonists [3]. As a
consequence, these drugs have detrimental eﬀects on alert-
ness, memory, postural stability, and muscle tone. In loss-
of-function studies conducted in point-mutated mice [4],
diﬀerent subtypes of GABAA receptors have been found
responsible for the speciﬁc aspects of benzodiazepine phar-
macology: (1) α1-containing receptors are associated with
sedative eﬀects of benzodiazepines [5, 6]; (2) α2/α3-con-
tainingreceptorsarerelatedtoanxiolysisandanalgesia[7,8];
(3) α5-receptors are associated with cognition [9, 10]. BZDs
exert their CNS actions in a concentration-related manner
[11]. The anxiolytic, hypnotic, muscle relaxant, and amnesic
eﬀects of BZDs generally appear concomitantly, and the
onset and duration of action of the compounds correlate
closely with their pharmacokinetic properties. The eﬀect
proﬁle of BZDs has been attributed to their non-selective
agonism at the α1, α2, α3,a n dα5 subunit-containing GABAA
receptors. To improve the pharmacological and functional
selectivity, novel GABAergic anxioselective compounds are2 Advances in Pharmacological Sciences
Table 1: In vitro pharmacological property of the GABAergic compounds.
Compound α1 α2 α3 α5 α1/α2-ratio
Ki (nM) Eﬃcacy◦ (%) Ki (nM) Eﬃcacy◦(%) Ki (nM) Eﬃcacy◦(%) Ki (nM) Eﬃcacy◦ (%)
TPA023∗ [26]0 . 2 7 0 # 0.31 11 0.19 21 0.41 5 0
TPACMP2∗ [13] 0.22 18 0.40 23 0.21 45 0.23 18 0.78
SL65.1498# [28] 17 45 73 115 80 83 215 48 0.39
Zolpidem 20 [29]7 5 § [30] 400 [29]7 8 § [30] 400 [29]8 0 § 5000 [29]9 § [30]0 . 9 6
◦Relative eﬃcacy is deﬁned as the extent of the potentiation of GABA-A EC20-equivalent current produced by the compound compared to that produced by
a nonselective full agonist (chlordiazepoxide/diazepam).
∗Mean values of 3 experiments in Xenopus oocytes with human recombinant αβ3γ2r e c e p t o r s ;e ﬃcacy relative to chlordiazepoxide.
#Mean values of 3 experiments in hek293 cells with recombinant rat receptors αβ2γ2; eﬃcacy relative to chlordiazepoxide.
§Mean values of 3 experiments in Xenopus oocytes with human recombinant αβ2γ2r e c e p t o r ;e ﬃcacy relative to diazepam.
Table 2: Component tests of the Neurocart battery and the related CNS domains.
Neurocart test Targeted function Related CNS areas
Saccadic eye movement Neurophysiologic function Superior colliculus, substantia nigra, amygdala
Smooth pursuit Neurophysiologic function Midbrain
Adaptive tracking Visuomotor coordination Neocortex, basal nuclei, brain stem, cerebellum
Body sway Balance Cerebellum, brain stem
Visual verbal learning test (VVLT) Memory Hippocampus
VAS Bond and Lader Alertness, mood, calmness Cortex, prefrontal cortex
VAS Bowdle Feeling high, internal and external perception Cortex, prefrontal cortex, amygdala
evaluated using recombinant human GABAA receptors dur-
ing preclinical development. The GABAergic eﬀect proﬁle of
a compound is characterized by the aﬃnity of the ligand for
the receptor and by the in vitro eﬃcacy of the compound at
each GABAA receptor subtype. In the past years, several par-
tial GABAA agonists have been developed, which have a rel-
atively high in vitro eﬃcacy at α2/α3 subtypes compared with
α1 orα5 subtypes.Suchα2/α3 subtype-selectivepartialGABA
agonists are anticipated to have favorable therapeutic eﬀect
and to be less sedating or cognition impairing (Table 1).
Based on nonclinical investigations with in vitro assays
and animal models of anxiety, the human pharmacology of
novel GABAergic agents is approached through sequential
clinical studies regarding pharmacokinetics, receptor occu-
pancy, and pharmacodynamics (PD) in healthy volunteers.
Direct links have been proposed between plasma drug con-
centration and receptor occupancy [4], as well as between
plasma drug concentration and pharmacodynamic parame-
ters [12–15]. Such pharmacokinetic/pharmacodynamic (PK/
PD) relationships warrant the assessment of surrogate bio-
markers in healthy volunteers treated with single doses of
selective novel GABAergic compound(s).
More than 170 pharmacodynamic tests or test variants
have been developed to assess the CNS eﬀects of benzodiaz-
epines [11]. De Visser et al. analyzed the interstudy consis-
tence, sensitivity, and pharmacological speciﬁcity of the fre-
quently used biomarkers. Saccadic peak velocity (SPV) and
visual analogue scale of alertness (VASalertness) were identiﬁed
as the most sensitive parameters for benzodiazepines. Both
testsshowedconsistenteﬀectstoavarietyofbenzodiazepines
at diﬀerent doses.
During the past ﬁfteen years, the Centre for Human
Drug Research (CHDR) has established a selection of
computerized neuropsycho-pharmacodynamic tests called
the Neurocart battery. The components of this battery target
a variety of neurophysiological and/or neuropsychological
domains (Table 2). Of this battery, adaptive tracking, sac-
cadiceyemovements,andbodyswaywereprovedsensitiveto
the sedating eﬀects of sleep deprivation [16], as well as ben-
zodiazepinesandotherGABAergicdrugs.Intherecentyears,
the Neurocart battery was used in a series of phase I studies
to assess CNS pharmacodynamics of partial α2,3 subtype
selective GABAA agonists. Both nonselective and/or selective
GABAA agonists were administered as single oral dose to
healthy volunteers. Clear distinctions of eﬀect proﬁle were
observed in these trials [12–14]. The objective of this paper
was to characterize the pharmacodynamic eﬀect proﬁles of
novel anxioselective GABAA agonists and identify suitable
biomarkers to distinguish α2,3 subtype-speciﬁc GABAA ago-
nists from full GABAA agonists like benzodiazepines.
2. Methods
Five clinical studies, all of which are published [12–15, 17],
were conducted at the CHDR in healthy volunteers
after approval from the Ethics Review Board of Leiden
University Medical Centre. All subjects provided written
inform consent for study participation. Each trial was
designed as single-dose, cross-over or parallel-armed,
randomized, double-blind, placebo- and/or positive-
controlled study. The subjects took single oral doses of
a selective GABAergic compound, placebo-, and/or a
nonselective benzodiazepine. Three studies used lorazepam
2mg as a positive control, whereas in the studies with
zolpidem 10mg and alprazolam 1mg, these drugs were the
only GABAergic study medications. Data of all studies cameAdvances in Pharmacological Sciences 3
from the same research center and were pooled from the
studies-speciﬁc electronic databases kept by the center. In
vitro pharmacological parameters of novel compounds were
extracted from the Investigator’s Brochures and published
articles. These parameters provide reliable information
about the subtype selectivity of each compound, but it is
more diﬃcult to compare the pharmacological properties
between the drugs. Due to the diversity of cell types and
GABAA receptor homologies used in the whole-cell patch
clamping assays, the links between in vitro pharmacology
and human in vivo eﬀects are considered less quantitative
and semiquantitative comparisons are preferred.
2.1. Treatments. Three novel drugs designed to be α2,3
subtypeselectiveweredosedinthreeoftheabove-mentioned
studies (for each dose group, the number of study partic-
ipants is provided in parentheses): TPA023 0.5mg, 1.5mg
(n = 12) [12]; TPACPM2 (MK0343) 0.25mg, 0.75mg (n =
12) [13]; SL65.1498 2.5mg, 7.5mg, and 25mg (n = 20)
[14]. Zolpidem is a hypnotic with a high aﬃnity for α1-
subtypes, and alprazolam is a nonselective GABAergic anx-
anxiolyticiolytic. Zolpidem 10mg (N = 14) [15]a n d
alprazolam 1mg (N = 20) were administered in another two
studies, respectively.
2.2. Pharmacodynamic Assessments
2.2.1. Saccadic Eye Movement. Saccadic eye movements are
very sensitive to a variety of mostly CNS-depressant drugs
[18, 19]. Saccadic peak velocity has been shown to be
closelyrelatedtotheanxiolyticpropertiesofbenzodiazepines
[4]. Since partial α2,3-subtype-selective GABAA agonists
are developed to be anxiolytic, it was expected that these
compounds would reduce saccadic peak velocity, similar to
what is typically observed with benzodiazepines. Therefore,
saccadic peak velocity was used as a biomarker for the
anxiolytic properties of the GABAA agonists, to which all
other pharmacodynamics eﬀects were compared in this
meta-analysis. Recording and analysis of saccadic eye move-
ments was conducted with a microcomputer-based system
for sampling and analysis of eye movements. The program
for signal collection and the AD converter were from
Cambridge Electronic Design (CED Ltd., Cambridge, UK),
the ampliﬁers were supplied by either Nihon Kohden (Nihon
Kohden, Life Scope EC, Tokyo, Japan) or Grass (Grass-
Telefactor, An Astro-Med, Inc. Product Group, Braintree,
USA), and the sampling and analysis scripts were developed
at CHDR (Leiden, The Netherlands).
2.2.2. Smooth Pursuit. T h es a m es y s t e m sa su s e df o rs a c c a d i c
eye movements were also used for measuring smooth pur-
suit. For smooth pursuit eye movements, the target moves
sinusoidally at frequencies ranging from 0.3 to 1.1Hz, in
steps of 0.1Hz. The amplitude of target displacement cor-
responds to 22.5 degrees eyeball rotation to both sides.
Four cycles were recorded for each stimulus frequency. The
method has been validated at CHDR by Van Steveninck
based on the work of Bittencourt et al. [20] and the original
description of Baloh et al. [21].
2.2.3. Visual Analogue Scales (VASs). Visual analogue scales
as originally described by Norris [22] were used previously
to quantify subjective eﬀects of benzodiazepines [19]. From
the set of sixteen scales, three composite factors were derived
a sd e s c r i b e db yB o n da n dL a d e r[ 23], corresponding to
alertness, mood, and calmness. These factors were used to
quantify subjective drug eﬀects.
2.2.4. Body Sway. The body sway meter measures body
movementsinasingleplane,providingameasureofpostural
stability. Body sway was measured with an apparatus similar
to the Wright ataxiameter, which integrates the amplitude of
unidirectional body movement transferred through a string
attached to the subject’s waist. Two-minute measurements
were made in the anteroposterior direction with eyes open
and closed, with the subject standing comfortably on a
ﬁrm surface with their feet slightly apart. The method has
been used before to demonstrate postural instability due to
benzodiazepines [24, 25].
2.2.5. Adaptive Tracking. The adaptive tracking test as
developed by Hobbs and Strutt was used, according to
speciﬁcationsofAtacketal.[26].Theadaptivetrackingtestis
a pursuit-tracking task. A circle of known dimensions moves
randomly across a screen. The test subject must try to keep
a dot inside the moving circle by operating a joystick. If this
eﬀortwassuccessful,thespeedofthemovingcircleincreases.
Conversely,thevelocitywasreducedifthetestsubjectcannot
maintain the dot inside the circle. The adaptive tracking test
is a measure of visuomotor coordination that has proved to
be very sensitive of various psychoactive drugs [27].
Table 3 summarizes the pharmacodynamic tests used in
the diﬀerent studies.
2.3. Statistical Analysis. Individual graphs are generated for
each pharmacodynamic variable (y-axis) versus SPV change
from baseline (x-axis). Summary graphs are generated with
lorazepam and one other treatment per graph, for all
GABAergic treatments.
A regression analysis of change from baseline of
body sway (ΔSway), tracking (ΔTrack), VAS alertness
(ΔVASalertness), or VAS calmness (ΔVAScalmness) against the
change from baseline of SPV (ΔSPV) was performed with
am i x e de ﬀect model on the available individual data. The
ﬁxed factor was the GABAergic treatment and treatment by
saccadic peak velocity, while the random factors were subject
slope and intercept. The values of body sway were analyzed
after log-transformation, while the other parameters were
taken without transformation. The estimates of the slopes
of the linear relations of these ΔSPV-relative eﬀect proﬁles
were compared between each dose of subtype-selective
GABAA agonists and lorazepam. The estimates of slopes,
their estimated diﬀerence, and the P values were tabulated.
Thereafter, summary plots were generated, combined with
the population regression line as calculated in the regression.
All statistical analyses were carried out with SAS for
Windows v9.1.3 (SAS institute, inc., Cary, NC, USA).4 Advances in Pharmacological Sciences
Table 3: Use of pharmacodynamic tests in each study.
Study CHDR99112 CHDR0102 CHDR0105 CHDR0614 CHDR0407
compound TPA023 TPACMP2 SL65.1498 Alprazolam Zolpidem
comparator Lorazepam Lorazepam Lorazepam NA NA
SEM Done Done Done Done Done
Sway Done Done Done Done Done
VAS BL Done Done Done Done Done
Smooth ND ND Done Done Done
Track ND ND ND Done Done
ND: not done; NA: not applicable; SEM: saccadic eye movement; Smooth: smooth pursuit; Sway: body sway; VAS BL: VAS Bond and Lader; Track: adaptive
tracking.
Table 4: Results of the linear model for saccadic peak velocity change from baseline and log body sway change from baseline by treatment
with treatment by SPV change from baseline as interaction.
Treatment ΔSPV-relative relation Item Estimate of treatment Estimate of lorazepam P value
TPA023 1.5mg
ΔSway-ΔSPV Slope −0.00048 −0.00305 <0.0001
Intercept −0.01316 0.1292 <0.0001
ΔVASalertness-ΔSPV Slope 0.03312 0.126 0.0001
Intercept 0.4551 −4.4739 0.0021
TPACMP2 0.75mg
ΔSway-ΔSPV Slope −0.00027 −0.00305 <0.0001
Intercept 0.03784 0.1292 0.0009
ΔVASalertness-ΔSPV Slope 0.09884 0.126 0.2525
Intercept −1.4465 −4.4739 0.0397
SL65.1498 25mg
ΔSway-ΔSPV Slope −0.00128 −0.00305 0.0003
Intercept 0.0222 0.1292 <0.0001
ΔVASalertness-ΔSPV Slope 0.04193 0.126 0.0009
Intercept 0.2453 −4.4739 <0.0001
ΔSmooth-ΔSPV Slope 0.01554 0.1099 <0.0001
Intercept −1.4483 −6.2553 <0.0001
Alprazolam 1mg
ΔSway-ΔSPV Slope −0.00204 −0.00305 0.0667
Intercept 0.001788 0.1292 <0.0001
ΔVASalertness-ΔSPV Slope 0.0734 0.126 0.0763
Intercept −0.628 −4.4739 0.0254
ΔTrack-ΔSPV Slope 0.0747 0.0572 0.1545
Intercept 0.3023 −4.0742 <0.0001
ΔSmooth-ΔSPV Slope 0.08077 0.1099 0.2808
Intercept −1.4025 −6.2553 0.0002
Zolpidem 10mg
ΔSway-ΔSPV Slope −0.0033 −0.00305 0.7336
Intercept 0.06014 0.1292 0.0127
ΔVASalertness-ΔSPV Slope 0.1526 0.126 0.5231
Intercept −3.2697 −4.4739 0.5219
ΔTrack-ΔSPV Slope 0.0489 0.0572 0.6240
Intercept −0.9123 −4.0742 <0.0001
ΔSmooth-ΔSPV Slope 0.09771 0.1099 0.7412
Intercept −3.8439 −6.2553 0.0815
3. Results
3.1. ΔSPV-ΔSway Relation (Δ = Change from Baseline). Av-
erage changes from baseline of body sway against SPV within
the investigational time course (i.e., 6 hours after dose) were
plotted by study. Figure 1 demonstrates clear distinctions
between the ΔSPV-relative eﬀect proﬁle of lorazepam 2mg
and most doses of the α2,3-subtype selective compounds
(i.e., TPA023 1.5mg, TPACMP2 0.75mg). The full GABAA
agonist alprazolam is similar to lorazepam. The slope of the
ΔSPV-ΔSway plots for zolpidem is slightly steeper than for
lorazepam.
As was revealed by the statistical analysis using the
mixed linear model (Table 4), the estimated diﬀerencesAdvances in Pharmacological Sciences 5
Predicted lorazepam
Predicted TPA023
−0.2
−0.1
0
0.1
0.2
0.3
0.4
0.5
SPV (deg/s) change from baseline
−120 −80 −40 0
Lorazepam 2 mg
TPA023 1.5 mg
L
o
g
 
b
o
d
y
 
s
w
a
y
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
l
o
g
(
m
m
)
)
(a)
Predicted lorazepam
Predicted TPACMP2
−0.2
−0.1
0
0.1
0.2
0.3
0.4
0.5
SPV (deg/s) change from baseline
−120 −80 −40 0
Lorazepam 2 mg
TPACMP2 0.75 mg
L
o
g
 
b
o
d
y
 
s
w
a
y
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
l
o
g
(
m
m
)
)
(b)
Predicted lorazepam
Predicted SL65.1498
−0.2
−0.1
0
0.1
0.2
0.3
0.4
0.5
SPV (deg/s) change from baseline
−120 −80 −40 0
Lorazepam 2 mg
SL65.1498 25 mg
L
o
g
 
b
o
d
y
 
s
w
a
y
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
l
o
g
(
m
m
)
)
(c)
Predicted lorazepam
Predicted zolpidem
−0.2
−0.1
0
0.1
0.2
0.3
0.4
0.5
SPV (deg/s) change from baseline
−120 −80 −40 0
Lorazepam 2 mg
Zolpidem 10 mg
L
o
g
 
b
o
d
y
 
s
w
a
y
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
l
o
g
(
m
m
)
)
(d)
Predicted lorazepam
Predicted alprazolam
−0.2
−0.1
0
0.1
0.2
0.3
0.4
0.5
SPV (deg/s) change from baseline
−120 −80 −40 0
Lorazepam 2 mg
Alprazolam 1 mg
L
o
g
 
b
o
d
y
 
s
w
a
y
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
l
o
g
(
m
m
)
)
(e)
Figure 1: ΔLogSway (log mm)-ΔSPV (deg/sec) relative eﬀect proﬁle of TPA023 1.5mg, TPACMP2 0.75mg, SL65.1498 25mg, zolpidem
10mg, and alprazolam 1mg versus lorazepam 2mg, respectively. (Blue open square: investigational compound; red closed circle: lorazepam
2mg; blue dot line: the comparator drug; red dash line: lorazepam 2mg.)6 Advances in Pharmacological Sciences
of the slope of regression lines are statistically signiﬁcant
between lorazepam and the α2,3 subtype selective partial
GABAergictreatmentofTPA0231.5mg,TPACMP20.75mg,
and SL65.1498 25mg. There is no statistically signiﬁcant
diﬀerence between the slopes for lorazepam and alprazolam,
and the diﬀerence with zolpidem suggested by the average
plots (Figure 1) is not conﬁrmed by the model (Table 4).
3.2. ΔSPV-ΔVASalertness Relation. Figure 2 plots the average
values of ΔVASalertness versus ΔSPV obtained from individual
subjects per study. As was found for the ΔSPV-ΔSway
relations, a similar diﬀerence to lorazepam was observed
with novel subtype selective GABAergic compounds. The
slopes of the regression line of the ΔSPV-ΔSway relation
for TPA023 1.5mg and SL65.1498 25mg are statistically
shallower than the slope for lorazepam, respectively. No
statistical diﬀerences can be demonstrated for TPACMP2
0.75mg, alprazolam 1mg, or zolpidem 10mg.
3.3. ΔSPV-ΔSmooth Relation. Figure 3 and Table 4 provide
the ΔSPV-relative eﬀect proﬁles and the slopes and inter-
cept for smooth pursuit after alprazolam, zolpidem, and
SL65.1498. Smooth pursuit was not determined with the
other partial agonists. Statistically signiﬁcant diﬀerences
are found in the slope of regression lines with SL65.2498
25mg. Zolpidem and alprazolam show comparable slopes to
lorazepam.
3.4. ΔSPV-ΔPD Relations versus In Vitro Pharmacologi-
cal Properties. This analysis surmises that comparisons of
ΔSPV-ΔPD proﬁles represent the underlying pharmaco-
logical characteristics of subtype selective and nonselective
GABAA agonists. A further corroboration of this approach
could be provided by a comparison of ΔSPV-ΔPD proﬁles
with the underlying pharmacological properties. This should
be possible in principle, but the quantitative preclinical
information provided in Table 1 was derived from diﬀerent
sources which in themselves were incomparable, despite
the fact that all programs used oocyte-clamp assays to
characterize the diﬀerent GABAergic compounds. Some of
these diﬀerences could be diminished by calculation of the
ratio of relative eﬃcacy on the α1 GABAA subunit to that
on the α2 subunit, as a benchmark of α2-speciﬁcity of the
GABAergic compounds. This calculated ratio is provided
in Table 1. Although the number of compounds in this
overview is too small for any meaningful statistical evalu-
ation, it is interesting that the four compounds for which
this could be calculated showed a close relationship between
α1/α2-eﬃcacy ratios and ΔSPV-ΔVAS alertness ratios with
borderline statistical signiﬁcance (r2 = 0.86, two-sided P =
0.0727). Due to the absence of in vitro pharmacological data
and the diﬀerence of experimental settings of the trail with
alprazolam, alprazolam was not included into the present
analysis.
4. Discussion
This analysis was performed to explore the central nervous
system (CNS) eﬀects of various GABAergic agents and
characterize the pharmacodynamic eﬀect proﬁles of these
compounds in healthy volunteers and correlate such proﬁles
to their pharmacological properties.
A battery of CNS pharmacodynamic tests was adminis-
tered to healthy volunteers who were dosed with GABAergic
compound(s). The composition of the CNS battery was
based on the sensitivity of the measurements to nonselective
GABAergic treatments, and on the coverage of a wide range
of diﬀerent CNS domains (Table 2). This approach enabled
us to identify unique eﬀect proﬁles for pharmacologically
distinct GABAergic treatments, including (1) traditional,
pharmacologically nonselective, full GABAergic compounds
at their clinical dose(s) (i.e., lorazepam 2mg and alprazolam
1mg), (2) a marketed GABAergic compound with high α1-
subtype aﬃnity (i.e., zolpidem 10mg), and (3) several novel,
α2,3-subtype selective GABAergic compounds at diﬀerent
investigational doses.
The new class of partial subtype selective GABA agonists
was expected to be anxiolytic but less sedating and cognition
impairing, as indicated by the preclinical in vitro and in
vivo data. The anxiolytic eﬀects of nonselective GABAergic
agonists are accompanied by somnolence, impaired locomo-
tion, and cognitive disturbance. These clinical side eﬀects are
reﬂected by the pharmacodynamics eﬀects of lorazepam or
alprazolam on VASalertness (measure of subjective sedation),
body sway (measure of postural instability), and adaptive
tracking (measure of visuomotor coordination). Memory
testing was not performed frequently and consistently
enough to allow a comparative analysis among the diﬀer-
ent compounds. However, the original publication of the
TPA023-study provides indications that the partial subtype
selective GABA agonist has fewer cognitive eﬀects than
the partial subtype selective GABA agonist. In this study,
lorazepam 2mg showed clear memory reductions, which
did not occur with a dose of TPA023 1.5mg that caused
comparable SPV reductions [12].
Saccadic peak velocity (SPV) has previously been shown
to be closely related to the anxiolytic doses of benzodiaz-
epines [11], and SPV was therefore used as a reference pa-
rameter. As expected, SPV showed signiﬁcant responses to
almost every GABAergic compound investigated in these six
studies [12–14]. In contrast to lorazepam or alprazolam,
which inﬂuenced each output parameter of the saccadic
eye movement test (i.e., SPV, saccadic reaction time, and
inaccuracy), the α1-(zolpidem) or α2,3-subtype selective
GABAergic compounds (TPA023, TPACMP2, SL65.1498)
only aﬀected SPV.
At their highest investigational dose, the eﬀect size of
TPA023 and TPACMP2 on SPV was comparable to the
eﬀects observed with lorazepam or alprazolam, whereas the
eﬀect of SL65.1498 was only marginally signiﬁcant on
SPV. In almost all these cases, the impact on other CNS
eﬀects was lower. This by itself is an indication of phar-
macological selectivity, but a comparison based merely on
overall or maximum eﬀects could obscure some of the more
subtle pharmacological diﬀerences (like the ﬁndings of
SL65.1498 study) when the pharmacodynamic biomarker
is less sensitive to the drug or if the dose of a drugAdvances in Pharmacological Sciences 7
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Figure 2:ΔVASalertness-ΔSPVrelativeeﬀect proﬁleof TPA0231.5mg,TPACMP20.75mg,SL65.1498 25mg,zolpidem 10mg,and alprazolam
1mg versus lorazepam 2mg, respectively. (Blue open square: investigational compound; red closed circle: lorazepam 2mg; blue dot line: the
comparator drug, red dash line; lorazepam 2mg.)8 Advances in Pharmacological Sciences
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Figure 3: ΔSmooth-ΔSPV relative eﬀect proﬁle of SL65.1498 25mg, zolpidem 10mg, and alprazolam 1mg versus lorazepam 2mg,
respectively. (Blue open square: investigational compound; red closed circle: lorazepam 2mg; blue dot line: the comparator drug, red dash
line; lorazepam 2mg.)
is subtherapeutic. The relationships between the ΔSPV-
eﬀects and other pharmacodynamic (ΔPD) eﬀects provide
ac o m p l e t ep r o ﬁ l eo ft h ed i ﬀerential eﬀects, at each time
point after drug administration. These outputs reﬂect the
degree of α2,3 selectivity and may therefore also be indi-
cators for anxioselectivity. Based on these perceptions, a
GABAergic compound with “ﬂat” regression lines in the
ΔSPV-relative plotting graphs would show anxiolysis with
reduced oﬀ-target eﬀects in clinical settings. For most of
the novel compounds described in this overview, there are
no clinical reports of anxiolytic eﬀects or improved tolera-
bility. However, a recent article on TPA023, the oldest
compound in this meta-analysis, reported reduced anxiety
in a preliminary clinical trial at doses that were also used in
our pharmacodynamic studies [4]. No detailed comparative
information is available on the therapeutic window in these
clinical trials.
We found that the ΔSPV-relative eﬀect proﬁles of α2,3
subtype-speciﬁc GABAergic compounds are similar among
each other but diﬀerent from lorazepam 2mg. The absolute
slopes of the regression lines for the ΔSPV-ΔPD relations
are generally lower with the selective GABAA agonists than
with the benzodiazepines. The results of alprazolam were
comparable to lorazepam, which provides additional conﬁ-
dence that the analyses reﬂect pharmacological diﬀerences
as well as similarities. Zolpidem seemed to be the only
major exception, since this α1 subtype-selective GABAergic
compound produced considerably steeper average slopes for
certain ΔSPV-relative proﬁles than lorazepam or alprazolam,
whereas the statistical population model did not reveal
statistically signiﬁcant diﬀerences between zolpidem and the
benzodiazepines. This could reﬂect a limitation of the popu-
lation model for ΔSPV-ΔPD relationships, which was chosen
to be simple and unbiased, but necessarily had to ignore
some rather complex individual response relationships. The
analyses were based on linear slope estimates without a
ﬁxed intercept. In reality, however, all individual data points
started at a ﬁxed intercept (at T = 0, when ΔSPV andAdvances in Pharmacological Sciences 9
ΔPD were both zero), and, in many cases, the ΔSPV-ΔPD
relationships were not linear, and zolpidem even formed
loops when the SPV eﬀect displayed a diﬀerent time course
than the PD eﬀect. In almost all other cases, however, the
statistical analyses and the graphical representations of the
average relationships provide accurate representations of the
individual plots.
This meta-analysis indicates that comparisons of ΔSPV-
ΔPD proﬁles are able to identify pharmacological diﬀerences
between subtype selective and nonselective GABAA agonists.
A comparison of ΔSPV-ΔPD proﬁles with the underlying
pharmacological properties was refuted by the very small
number of compounds for which this could be compared.
Nonetheless, strong relationships (with an R-value of 0.93)
between the α1/α2-ratios of the four compounds for which
this could be determined and their ΔSPV-ΔVASalertness ratios.
Clearly this remains to be conﬁrmed with larger numbers
of compounds. Still, the consistent ΔSPV-relative proﬁles
of the selective GABAergic compounds suggest potential
links between the preclinical proﬁles and the ΔSPV-relative
pharmacodynamics proﬁles of these compounds. Moreover,
TPACMP2 showed a distinct ΔSPV-ΔVASalertness relation but
shared a similar ΔSPV-ΔSway relation with the other α2,3-
subtype-selective GABAergic agonists. The relatively large
amount of sedation with TPACMP2 could reﬂect the rela-
tively high ratio of α1/α2-eﬃcacy of TPMCMP2 compared
to the other compounds. Similarly, the large eﬃcacy of
zolpidem is compatible with its steep ΔSPV-ΔVASalertness
ratio and the strong hypnosedative eﬀect of this z-hypnotic
in the clinic.
5. Conclusion
TPA023, TPACMP2, and SL65.1498 are members of the
novel experimental drug family of α2,3-subtype selective re-
ceptor agonists. In vitro pharmacological properties of these
compounds indicate higher binding aﬃnity and relative
eﬃcacy at the α2,3-subunits. In vivo preclinical studies with
animal models translated such pharmacological properties
into potential of anxiolysis and relatively reduced oﬀ-target
eﬀects in comparison with nonselective full GABAergic ago-
nists like benzodiazepines.
The Neurocart battery is a collection of validated tests
amenable to the eﬀects of various CNS-acting drugs. Com-
ponentsofthisbatterywereshowntobesensitivetodiﬀerent
rapid-onset CNS eﬀects of the benzodiazepines, in which
reduction of saccadic peak velocity displays features of a
GABAergic anxiolytic biomarker, whereas impairments of
body sway, adaptive tracking, and memory are translated
to eﬀects that are less desirable for an anxiolytic drug.
Most novel GABAergic compounds showed dose-dependent
responses to saccadic peak velocity but did not aﬀect the
other CNS eﬀects to the same extent, indicative of the phar-
macoselectivity of these new compounds. Moreover, the
ΔSPV-relative eﬀect proﬁles provide information about dose
potency and eﬀect speciﬁcity. This battery is suitable to not
onlypresentthegeneraldepressiveeﬀectsofbenzodiazepines
but also demonstrate the pharmacological selectivity and
speciﬁcityof thenovel GABAergic compounds. Comparative
eﬀect proﬁling as used in these studies can provide clear
indicationsforthepharmacologicalselectivityandspeciﬁcity
of novel GABAergic compounds in healthy volunteers. This
is a valuable approach for the early drug development of this
new drug class, which will hopefully contribute novel anx-
iolytics with an improved therapeutic window to patients
with anxiety disorders.
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